What is Global Human Rabies Vaccine Market?
The Global Human Rabies Vaccine Market is a comprehensive sector that focuses on the production and distribution of vaccines used to prevent rabies in humans. This market is of significant importance due to the deadly nature of the rabies virus, which is often transmitted through the bites of infected animals. The market encompasses various types of vaccines, including those made from Vero cells, Baby Hamster Kidney (BHK) cells, chick embryo cells, and human diploid cells. These vaccines are produced in laboratories and are designed to stimulate an immune response in the human body, thereby preventing the onset of rabies following exposure to the virus. The market also includes vaccines used for both pre-exposure and post-exposure prophylaxis. Pre-exposure vaccines are given to individuals who are at a high risk of exposure to the virus, such as veterinarians and animal handlers, while post-exposure vaccines are administered to individuals after they have been bitten by a potentially rabid animal. The Global Human Rabies Vaccine Market is a critical component of global health efforts aimed at eradicating rabies, a goal that is achievable through widespread vaccination and public education about the dangers of this deadly virus.
Vero Cell, BHK, Chick Embryo Cell, Human Diploid Cells, Others in the Global Human Rabies Vaccine Market:
The Global Human Rabies Vaccine Market is segmented based on the type of cell used in the production of the vaccine. These include Vero cells, Baby Hamster Kidney (BHK) cells, chick embryo cells, and human diploid cells. Vero cells are a line of cells that have been derived from the kidney of an African green monkey. These cells are used in the production of several different types of vaccines, including those for rabies. BHK cells, on the other hand, are derived from the kidney cells of a baby hamster. These cells are also used in the production of various vaccines, including those for rabies. Chick embryo cells are derived from the embryos of chickens and are used in the production of some types of rabies vaccines. Finally, human diploid cells are cells that have been derived from human tissue and are used in the production of some types of rabies vaccines. Each of these cell types has its own advantages and disadvantages in terms of vaccine production, and the choice of cell type depends on a variety of factors, including the specific requirements of the vaccine and the resources available for vaccine production.
Pre-Exposure Vaccine, Post-Exposure Vaccine in the Global Human Rabies Vaccine Market:
The Global Human Rabies Vaccine Market also includes vaccines used for both pre-exposure and post-exposure prophylaxis. Pre-exposure vaccines are given to individuals who are at a high risk of exposure to the rabies virus. This includes individuals who work with animals, such as veterinarians and animal handlers, as well as individuals who are traveling to areas where rabies is endemic. Pre-exposure vaccination involves a series of three vaccines given over a period of 28 days. Post-exposure vaccines, on the other hand, are given to individuals after they have been bitten by a potentially rabid animal. Post-exposure vaccination involves a series of five vaccines given over a period of 14 days, along with a dose of rabies immune globulin given at the time of the first vaccine. Both pre-exposure and post-exposure vaccines are critical components of efforts to prevent the onset of rabies following exposure to the virus.
Global Human Rabies Vaccine Market Outlook:
The Global Human Rabies Vaccine Market was valued at US$ 1056 million in 2023. It is projected to reach a value of US$ 1422.9 million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 4.3% during the forecast period from 2024 to 2030. The largest consumer of these vaccines is the Asia-Pacific region, which accounts for nearly 60% of the market. North America follows as the second-largest consumer, with a market share of over 15%. The Vero Cell rabies vaccines make up about 85% of the market. This data provides a snapshot of the current state of the Global Human Rabies Vaccine Market and offers insight into its potential growth and development in the coming years.
| Report Metric | Details |
| Report Name | Human Rabies Vaccine Market |
| Accounted market size in 2023 | US$ 1056 million |
| Forecasted market size in 2030 | US$ 1422.9 million |
| CAGR | 4.3% |
| Base Year | 2023 |
| Forecasted years | 2024 - 2030 |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | Bharat Biotech, Bavarian Nordic, Sanofi-Pasteur, Chengda Bio, KANGH, Prcmise, Henan Grand Biopharma, Zhuoyi Biological, ZhongKe Biopharm, Ningbo Rongan Biological, Indian Immunologicals |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
